Tesla shares drop after third-quarter profit falls short of estimates
McKesson Corporation’s stock has reached a new milestone, hitting an all-time high of 794.0 USD, with a market capitalization now approaching $99 billion. According to InvestingPro data, analysts see further potential upside, with price targets ranging from $680 to $900. This achievement reflects a remarkable 58.27% increase over the past year, with an impressive 38.4% gain year-to-date, underscoring the company’s robust performance and investor confidence. The pharmaceutical distribution giant has been on an upward trajectory, consistently outperforming market expectations and capitalizing on industry trends. InvestingPro analysis reveals two notable strengths: management has been aggressively buying back shares, and the company has maintained dividend payments for 32 consecutive years. This latest peak highlights McKesson’s strategic initiatives and operational efficiencies that have driven its stock to unprecedented levels, marking a significant moment in its market journey. Based on InvestingPro’s Fair Value analysis, the stock appears fairly valued at current levels. Discover 16 additional exclusive ProTips and comprehensive analysis in the Pro Research Report, available with an InvestingPro subscription.
In other recent news, McKesson has seen a series of adjustments in its stock price targets from various analyst firms. TD Cowen raised its price target to $864 from $830, maintaining a Buy rating, following McKesson’s Investor Day where the company increased its long-term earnings per share guidance. UBS also raised its price target to $860 from $820, citing McKesson’s strong cash flow and strategic focus on growth markets. Mizuho increased its target to $770 from $750, noting the company’s revised EPS growth guidance of 13-16%, which addresses concerns about industry slowdown. Leerink Partners set a new target of $850, up from $785, due to promising growth in McKesson’s pharmaceutical segments. Conversely, Jefferies lowered its target to $84 from $90, citing tariff and geopolitical pressures, although they maintained a Buy rating as McKesson upheld its fiscal year guidance. These developments reflect a mixed sentiment among analysts, with most expressing confidence in McKesson’s strategic direction and growth prospects.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.